You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on breast cancer.
Adding Verzenio to hormone therapy reduced the risk of relapse by 25 percent, while the PALLAS study, testing another CDK4/6 inhibitor, failed.
The research showed that atezolizumab plus nab-paclitaxel provided survival benefits, as did an antibody-drug conjugate that was recently approved by the FDA.
Two new studies show that patients with advanced HR-positive, HER2-negative breast cancer had higher survival when they received combination therapies.
The drug giant will be responsible for globally developing and commercializing the compound, called Erso, currently in preclinical development.
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
The statement is based on the IMpassion131 trial, in which the combination did not improve survival endpoints compared to paclitaxel in PD-L1-positive patients.
Adult participants will have access to saliva-based testing from Invitae for the Screen Project, which aims to find clinically actionable BRCA1/2 mutations.
The trial will assess the safety and tolerability of Zion's ZN-A-1041 in patients with HER2-positive tumors, including those with brain metastases.
A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and were associated with lower response to aromatase inhibitors.
Results of the randomized Phase III BROCADE trial, recently published in The Lancet Oncology, suggested a benefit of veliparib combined with platinum-based chemotherapy.